Search research articles
Contact Us
Filters
Showing results (91-100 of 164) with videos related to
Page
of 17
Sort By:
British Journal of Haematology
|
January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
Nam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Journal of Ovarian Research
|
December 6, 2014
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
Ayala Tamir, Ushma Jag, Sreeja Sarojini, et al.
Transplantation and Cellular Therapy
|
May 15, 2026
Consolidation Therapy with Checkpoint Inhibitors after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma
Lindsay Fogel, Patrick C Roney, Jaeil Ahn, et al.
British Journal of Haematology
|
June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Lei Feng, et al.
World Journal of Gastrointestinal Pharmacology and Therapeutics
|
June 27, 2025
Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies
Ayrton Bangolo, Behzad Amoozgar, Maryam Habibi, et al.
British Journal of Haematology
|
June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ranjana H Advani, Daniel Lebovic, Andy Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
Nam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
The Oncologist
|
September 30, 2018
A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs
Stuart L Goldberg, Dhakshila Paramanathan, Raya Khoury, et al.
Cancer
|
January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
Jorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 164) with videos related to
Sort By:
Page
of 17
British Journal of Haematology
|
January 20, 2007
Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma
Nam H Dang, Barbara Pro, Fredrick B Hagemeister, et al.
Journal of Ovarian Research
|
December 6, 2014
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes
Ayala Tamir, Ushma Jag, Sreeja Sarojini, et al.
Transplantation and Cellular Therapy
|
May 15, 2026
Consolidation Therapy with Checkpoint Inhibitors after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma
Lindsay Fogel, Patrick C Roney, Jaeil Ahn, et al.
British Journal of Haematology
|
June 10, 2010
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E Romaguera, Luis E Fayad, Lei Feng, et al.
World Journal of Gastrointestinal Pharmacology and Therapeutics
|
June 27, 2025
Exploring the gut microbiome's influence on cancer-associated anemia: Mechanisms, clinical challenges, and innovative therapies
Ayrton Bangolo, Behzad Amoozgar, Maryam Habibi, et al.
British Journal of Haematology
|
June 28, 2013
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
Fredrick Hagemeister, Maria Alma Rodriguez, Steven R Deitcher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 8, 2016
Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ranjana H Advani, Daniel Lebovic, Andy Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 9, 2004
Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma
Nam H Dang, Fredrick B Hagemeister, Barbara Pro, et al.
The Oncologist
|
September 30, 2018
A Patient-Reported Outcome Instrument to Assess Symptom Burden and Predict Survival in Patients with Advanced Cancer: Flipping the Paradigm to Improve Timing of Palliative and End-of-Life Discussions and Reduce Unwanted Health Care Costs
Stuart L Goldberg, Dhakshila Paramanathan, Raya Khoury, et al.
Cancer
|
January 28, 2003
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
Jorge E Romaguera, L Jeffrey Medeiros, Frederick B Hagemeister, et al.
Page
of 17